{"entity":{"id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","aka":[],"tldr":"A phase 1/2 trial of SLOG + Allogeneic NK cell in pancreatic ductal adenocarcinoma and biliary tract cancer, run by Medigen Biotechnology Corporation, now recruiting.","summary":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients is a phase 1/2 interventional study registered as NCT06730009 by Medigen Biotechnology Corporation, with 42 participants planned, started 2024-10-21 and due to reach its primary completion in 2029-01-31. Interventions recorded: SLOG + Allogeneic NK cell and SLOG chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06730009","url":"https://clinicaltrials.gov/study/NCT06730009"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06730009","phase":"1/2","setting":"A Dose-Finding Phase I Followed by a Phase II Study to Evaluate the Safety and Efficacy of Allogeneic NK-cell Combined With Chemotherapy in Patients With PDA or Cholangiocarcinoma After Surgery","sponsor":"Medigen Biotechnology Corporation","enrolled":42,"outcomes":[]},"route":"/trials/nct06730009/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}